Company intelligence / Profile preview

Ingalls & Snyder

New York City, New York, United States

Ownership: Private
Employees: ~81
Development stage: Other

Overview

Ingalls & Snyder provides custom investment management, financial planning, and wealth advisory services, notably for high-net-worth individuals and institutions, with approximately $10.5 billion in assets under management as of March 2025. The firm is employee-owned and has served clients for over a century since its founding in 1924.

Industry: Investors

Partnerships

None in biotech or pharma; as financier, has interacted with healthcare/biotech (e.g., acted as collateral agent for Akela Pharma); no direct R&D partnerships.

Beyond the preview

Go deeper on Ingalls & Snyder.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingalls & Snyder.

Explore the full profile